Table 3.

BM characteristics at follow-up time points

Parameterd 15d 33wk 12wk 22-24
Total NC count3-150 4.3  (0.6-45) 7.3  (0.9-32) 15.7  (2-120) 24.2  (2.4-75) 
Normal B cells3-151 14.6  (0.5-40) 5.3  (0.3-40) 1.2  (0.01-9) 2.2  (0.04-19)  
BCP 13-152 0.0  (0.0-0.0) 0.0  (0.0-0.0) 51.0  (0.0-99) 44.5  (0.0-95)  
BCP 23-152 0.0  (0.0-5.0) 0.0  (0.0-1.0) 7.3  (0.0-57) 25.7  (0.0-61) 
BCP 33-152 99.9  (95-100) 98.2  (97.6-100) 8.7  (0.0-82) 6.8  (0.0-48)  
Plasma cells3-152 0.1  (0.0-0.9) 1.2  (0.0-2.4) 7.6  (0.0-77) 4.7  (0.0-80)  
Threshold3-153 0.013  (0.001-0.32) 0.01  (0.001-0.14) 0.065  (0.002-2.7) 0.07  (0.002-2.6) 
Parameterd 15d 33wk 12wk 22-24
Total NC count3-150 4.3  (0.6-45) 7.3  (0.9-32) 15.7  (2-120) 24.2  (2.4-75) 
Normal B cells3-151 14.6  (0.5-40) 5.3  (0.3-40) 1.2  (0.01-9) 2.2  (0.04-19)  
BCP 13-152 0.0  (0.0-0.0) 0.0  (0.0-0.0) 51.0  (0.0-99) 44.5  (0.0-95)  
BCP 23-152 0.0  (0.0-5.0) 0.0  (0.0-1.0) 7.3  (0.0-57) 25.7  (0.0-61) 
BCP 33-152 99.9  (95-100) 98.2  (97.6-100) 8.7  (0.0-82) 6.8  (0.0-48)  
Plasma cells3-152 0.1  (0.0-0.9) 1.2  (0.0-2.4) 7.6  (0.0-77) 4.7  (0.0-80)  
Threshold3-153 0.013  (0.001-0.32) 0.01  (0.001-0.14) 0.065  (0.002-2.7) 0.07  (0.002-2.6) 
F3-150

Total nucleated cells (including erythroid precursors) × 109/L; median (range); tested BM samples: day 15, n = 101; day 33, n = 103; week 12, n = 66; weeks 22-24, n = 54.

F3-151

Percentage of CD19+ B cells among NCs; median (range); tested BM samples: day 15, n = 92; day 33, n = 93; week 12, n = 62; weeks 22-24, n = 47.

F3-152

Proportion of BCP stage among total CD19+ B cells; median (range); tested BM samples: day 15, n = 87; day 33, n = 94; week 12, n = 34; weeks 22-24, n = 32.

F3-153

Threshold proportions of NC at/above which samples were definitely MRD, median (range); the threshold characterizes the test sensitivity in MRD BM samples: day 15, n = 11; day 33, n = 62; week 12, n = 55; week 22-24, n = 48.

or Create an Account

Close Modal
Close Modal